Ludwig Enterprises, Inc. (OTC: LUDG), a US-based biotechnology company, is excited to announce the successful filing of its provisional patent titled "mRNAs Differentially Expressed in Colorectal Cancer, Breast Cancer, and Bladder Cancer." Through the utilization of machine learning artificial intelligence (AI), the company has achieved a breakthrough in identifying specific mRNA genes associated with breast, colorectal, and bladder cancer.

This achievement represents a significant milestone for the company, positioning it to enter the billion-dollar diagnostic cancer screening market this year. Ludwig's mRNA for Life™ introduces a revolutionary noninvasive at-home screening test for genes potentially linked to cancer, empowering individuals to prioritize their health and prompting them to seek medical evaluation if necessary.

Over the past three years, Ludwig has collected over 2,500 noninvasive cheek cell samples from various clinics across the United States as part of an IRB-approved clinical study involving patients with different diseases. The company has carefully selected 48 distinct mRNA genes for measurement in stored specimens from patients affected by breast, bladder, or colorectal cancer. Utilizing machine learning AI, mRNA levels were analyzed to identify markers of genetic expression associated with different cancer types. The filed patent application outlines a method for using buccal or cheek cells as surrogate tissues to isolate sufficient nanogram amounts of mRNA, which can then be measured using proprietary custom-designed microarray chips produced by Thermo Fisher Scientific for Ludwig. Buccal cells are considered ideal surrogate tissues for studying mRNA levels.

Epigenetic regulation via mRNA plays a crucial role in cellular control during cancer development. The complex process of cancer development involves various factors such as growth factors, cytokines, and extracellular enzymes, which shape the tissue environment and influence cancer progression. Understanding the elements of mRNA transcripts that influence the epigenome within each cell type during cellular reprogramming events, as well as how the evolving epigenomes within tumors and surrounding stroma interact synergistically during tumor progression, is paramount.

Epigenetics examines how an individual's behaviors and environment can induce changes that impact gene functionality. Unlike genetic alterations, epigenetic changes are reversible and do not alter the DNA sequence. However, they can alter how the body interprets a DNA sequence.

Dr. Marvin S. Hausman, CEO, commented, "We may have uncovered a potential breakthrough in medicine by leveraging mRNA genetic information to enable early and more accurate disease prediction and diagnosis. Through our innovative screening approach utilizing mRNA biomarkers, we have identified genetic predispositions to cancer, facilitating personalized treatment strategies and therapy response assessment."

 

Source: globenewswire.com

Report Abuse